Top 2 S&P 500 Stocks to Watch This Week After Hims & Hers Stock's Surprise Move

Hims & Hers ended its lawsuit with Novo Nordisk, helping HIMS shares rally (stock is in a 65% drawdown from highs but up ~50% in March). The deal highlights that pharmaceutical giants—Novo Nordisk and Eli Lilly—hold pricing and distribution power; both firms' revenues are up ~200% over the past 10 years and each generates >$15B in annual net income, while Hims & Hers is only marginally profitable as a reseller. Monitor NVO and LLY as sector leaders that could capture sustained upside if direct-to-patient delivery of weight-loss drugs expands demand.

Analysis

The immediate structural winner in the current setup is the manufacturer: control over supply, approval, and list pricing gives them asymmetric leverage over downstream distributors. Telehealth platforms functionally become customer-acquisition and last-mile logistics partners, not margin creators, so their valuation now depends on ability to drive adherence and reduce churn rather than capture drug economics. Expect specialty pharmacy, cold-chain logistics, and fulfillment partners to pick up incremental revenue as volume ramps; these service providers will be an under-the-radar beneficiary for the next 6–18 months.

Key tail risks are payer pushback and manufacturing constraints. Large-scale utilization and price negotiation by PBMs or government payers could compress realized prices within 12–36 months, and current capacity limits at peptide/biologic fill–finish facilities mean visible demand can outstrip supply quickly, creating short-term volatility and upside for manufacturers but sustained access problems for distributors. Regulatory scrutiny around distribution agreements and prior authorization enforcement is a 6–24 month catalyst that could reallocate margin between parties.

The consensus trade — long manufacturers, dismiss intermediaries — is directionally sensible but not binary. Telehealth platforms retain optionality: if they prove superior at conversion, adherence, and recurring refill economics, they can monetize via service fees/subscriptions and earn a higher multiple than the market currently assumes. That creates an asymmetric, option-like payoff for a small, financed exposure to high-quality telehealth operators while favoring larger, conviction positions in the manufacturers with capacity expansion visibility.

Key Decisions for Investors

• Pair trade (6–12 months): Long LLY equity or 12-month call spread (10–20% OTM) vs short HIMS equity sized 1:0.5 (dollar-neutral). Rationale: capture manufacturer margin expansion vs reseller margin compression. Target payoff: 30–50% upside on long leg if share gains persist; short leg expected to fall ~20–30% on margin squeeze. Stop-loss: 15% adverse move on the pair.
• Capacity-alpha trade (3–9 months): Buy NVO or LLY longer-dated calls (9–12 months, ~25% OTM) sized for 2–4% portfolio exposure ahead of quarterly manufacturing updates. Reward: asymmetric upside on realized volume expansion; Risk: premium decay and price concessions if payers impose discounts.
• Tactical hedge for telehealth optionality (3–6 months): Small long HIMS out-of-the-money call (3–6 month) as convexity play (<=1% portfolio). If the platform materially improves refill/adherence metrics, this position offers asymmetric upside with capped loss.
• Event-driven monitor: Short-term tactical shorts on telehealth peers or logistics-sensitive names on any signs of widened prior-auth bottlenecks or announced payer reimbursement limits. Timeframe: trade in the days to weeks after policy headlines; target 15–25% moves, sized to limit drawdown to 2% portfolio per event.